Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Immune triggers preceding neuralgic amyotrophy.
Sparasci D, Schilg-Hafer L, Schreiner B, Scheidegger O, Peyer A, Lascano A, Vicino A, Décard B, Tsouni P, Humm A, Pianezzi E, Zezza G, Hundsberger T, Dietmann A, Jung H, Kuntzer T, Wilder-Smith E, Martinetti-Lucchini G, Petrini O, Fontana S, Gowland P, Niederhauser C, Gobbi C, Ripellino P. Immune triggers preceding neuralgic amyotrophy. Eur J Neurol 2024; 31:e16462.
04.10.2024Immune triggers preceding neuralgic amyotrophy.
04.10.2024Eur J Neurol 2024; 31:e16462
Sparasci Davide, Schilg-Hafer Lenka, Schreiner Bettina, Scheidegger Olivier, Peyer Anne-Kathrin, Lascano Agustina Maria, Vicino Alex, Décard Bernhard Friedrich, Tsouni Pinelopi, Humm Andrea Monika, Pianezzi Enea, Zezza Giulia, Hundsberger Thomas, Dietmann Anelia, Jung Hans H, Kuntzer Thierry, Wilder-Smith Einar, Martinetti-Lucchini Gladys, Petrini Orlando, Fontana Stefano, Gowland Peter, Niederhauser Christoph, Gobbi Claudio, Ripellino Paolo
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
Wyss N, Berner F, Walter V, Jochum A, Purde M, Abdou M, Sinnberg T, Hofmeister K, Pop O, Hasan A, Bauer J, Cheng H, Lütge M, Klümper N, Diem S, Kosaloglu-Yalcin Z, Zhang Y, Sellmer L, Macek B, Karbach J, König D, Läubli H, Zender L, Meyer B, Driessen C, Schürch C, Jochum W, Amaral T, Heinzerling L, Cozzio A, Hegazy A, Schneider T, Brutsche M, Sette A, Lenz T, Walz J, Rammensee H, Früh M, Jäger E, Becher B, Tufman A, Núñez N, Jörger M, Flatz L. Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade. Am J Respir Crit Care Med 2024; 210:919-930.
01.10.2024Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
01.10.2024Am J Respir Crit Care Med 2024; 210:919-930
Wyss Nina, Berner Fiamma, Walter Vincent, Jochum Ann-Kristin, Purde Mette T, Abdou Marie-Therese, Sinnberg Tobias, Hofmeister Kathrin, Pop Oltin, Hasan Ali, Bauer Jens, Cheng Hung-Wei, Lütge Mechthild, Klümper Niklas, Diem Stefan, Kosaloglu-Yalcin Zeynep, Zhang Yizheng, Sellmer Laura, Macek Boris, Karbach Julia, König David, Läubli Heinz, Zender Lars, Meyer Britta S, Driessen Christoph, Schürch Christian M, Jochum Wolfram, Amaral Teresa, Heinzerling Lucie M, Cozzio Antonio, Hegazy AhN, Schneider Tino, Brutsche Martin, Sette Alessandro, Lenz Tobias L, Walz Juliane Sarah, Rammensee Hans-Georg, Früh Martin, Jäger Elke, Becher Burkhard, Tufman Amanda, Núñez Nicolás Gonzalo, Jörger Markus, Flatz Lukas
On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer.
Sinn B, Sychra K, Untch M, Karn T, van Mackelenbergh M, Huober J, Schmitt W, Marme F, Schem C, Solbach C, Stickeler E, Tesch H, Fasching P, Schneeweiss A, Müller V, Holtschmidt J, Nekljudova V, Loibl S, Denkert C. On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res 2024; 26:138.
24.09.2024On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer.
24.09.2024Breast Cancer Res 2024; 26:138
Sinn Bruno Valentin, Sychra Katharina, Untch Michael, Karn Thomas, van Mackelenbergh Marion T, Huober Jens, Schmitt Wolfgang Daniel, Marme Frederik, Schem Christian, Solbach Christine, Stickeler Elmar, Tesch Hans, Fasching Peter Andreas, Schneeweiss Andreas, Müller Volkmar, Holtschmidt Johannes, Nekljudova Valentina, Loibl Sibylle, Denkert Carsten
Improving outcome measures in late onset Pompe disease: Modified Rasch-Built Pompe-Specific Activity scale.
van Kooten H, Horton M, Wenninger S, Babačić H, Schoser B, Lefeuvre C, Taouagh N, Laforet P, Segovia S, Diaz-Manera J, Claeys K, Mongini T, Musumeci O, Toscano A, Hundsberger T, Brusse E, van Doorn P, van der Ploeg A, van der Beek N, European Pompe Consortium study group on outcome measures. Improving outcome measures in late onset Pompe disease: Modified Rasch-Built Pompe-Specific Activity scale. Eur J Neurol 2024; 31:e16397.
28.08.2024Improving outcome measures in late onset Pompe disease: Modified Rasch-Built Pompe-Specific Activity scale.
28.08.2024Eur J Neurol 2024; 31:e16397
van Kooten Harmke A, Horton Mike C, Wenninger Stephan, Babačić Haris, Schoser Benedikt, Lefeuvre Claire, Taouagh Najib, Laforet Pascal, Segovia Sonia, Diaz-Manera Jordi, Claeys Kristl G, Mongini Tiziana, Musumeci Olimpia, Toscano Antonio, Hundsberger Thomas, Brusse Esther, van Doorn Pieter A, van der Ploeg Ans T, van der Beek Nadine A M E, European Pompe Consortium study group on outcome measures
GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer.
Möbus V, Lück H, Ladda E, Klare P, Engels K, Schmidt M, Schneeweiss A, Grischke E, Wachsmann G, Forstbauer H, Untch M, Marme F, Blohmer J, Jackisch C, Huober J, Stickeler E, Reinisch M, Link T, Sinn B, Janni W, Denkert C, Seiler S, Solbach C, Schmatloch S, Rey J, Loibl S. GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer. NPJ Breast Cancer 2024; 10:66.
30.07.2024GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer.
30.07.2024NPJ Breast Cancer 2024; 10:66
Möbus Volker, Lück Hans-Joachim, Ladda Ekkehart, Klare Peter, Engels Knut, Schmidt Marcus, Schneeweiss Andreas, Grischke Eva-Maria, Wachsmann Grischa, Forstbauer Helmut, Untch Michael, Marme Frederik, Blohmer Jens-Uwe, Jackisch Christian, Huober Jens, Stickeler Elmar, Reinisch Mattea, Link Theresa, Sinn Bruno Valentin, Janni Wolfgang, Denkert Carsten, Seiler Sabine, Solbach Christine, Schmatloch Sabine, Rey Julia, Loibl Sibylle
HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.
Besse A, Sedlarikova L, Büchler L, Kraus M, Yang C, Strakova N, Soucek K, Navratil J, Svoboda M, Welm A, Jörger M, Driessen C, Besse L. HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer. Br J Cancer 2024
05.07.2024HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.
05.07.2024Br J Cancer 2024
Besse Andrej, Sedlarikova Lenka, Büchler Lorina, Kraus Marianne, Yang Chieh-Hsiang, Strakova Nicol, Soucek Karel, Navratil Jiri, Svoboda Marek, Welm Alana L, Jörger Markus, Driessen Christoph, Besse Lenka
A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers.
Spriano F, Sartori G, Sgrignani J, Barnabei L, Arribas A, Guala M, Del Amor A, Tomasso M, Tarantelli C, Cascione L, Golino G, Riveiro M, Bortolozzi R, Lupia A, Paduano F, Huguet S, Rezai K, Rinaldi A, Margheriti F, Ventura-Aguiar P, Guarda G, Costa G, Rocca R, Furlan A, Verdonk L, Innocenti P, Martin N, Viola G, Driessen C, Zucca E, Stathis A, Gahtory D, Van den Nieuwboer M, Bornhauser B, Alcaro S, Trapasso F, Cristobal S, Padrick S, Pazzi N, Cavalli F, Cavalli A, Gaudio E, Bertoni F. A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers. Haematologica 2024
20.06.2024A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers.
20.06.2024Haematologica 2024
Spriano Filippo, Sartori Giulio, Sgrignani Jacopo, Barnabei Laura, Arribas Alberto, Guala Matilde, Del Amor Ana Maria Carrasco, Tomasso Meagan R, Tarantelli Chiara, Cascione Luciano, Golino Gaetanina, Riveiro Maria E, Bortolozzi Roberta, Lupia Antonio, Paduano Francesco, Huguet Samuel, Rezai Keyvan, Rinaldi Andrea, Margheriti Francesco, Ventura-Aguiar Pedro, Guarda Greta, Costa Giosuè, Rocca Roberta, Furlan Alberto, Verdonk Luuk M, Innocenti Paolo, Martin Nathaniel I, Viola Giampietro, Driessen Christoph, Zucca Emanuele, Stathis Anastasios, Gahtory Digvijay, Van den Nieuwboer Maurits, Bornhauser Beat, Alcaro Stefano, Trapasso Francesco, Cristobal Susana, Padrick Shae B, Pazzi Natalina, Cavalli Franco, Cavalli Andrea, Gaudio Eugenio, Bertoni Francesco
Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024.
Schoser B, van der Beek N, Broomfield A, Brusse E, Diaz-Manera J, Hahn A, Hundsberger T, Kornblum C, Kruijshaar M, Laforet P, Mengel E, Mongini T, Orlikowski D, Parenti G, Pijnappel W, Roberts M, Scherer T, Toscano A, Vissing J, O'Sullivan J, van Doorn P, Wenninger S, van der Ploeg A. Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024. Eur J Neurol 2024; 31:e16383.
14.06.2024Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024.
14.06.2024Eur J Neurol 2024; 31:e16383
Schoser Benedikt, van der Beek Nadine A M E, Broomfield Alexander, Brusse Esther, Diaz-Manera Jordi, Hahn Andreas, Hundsberger Thomas, Kornblum Cornelia, Kruijshaar Michelle E, Laforet Pascal, Mengel Eugen, Mongini Tiziana, Orlikowski David, Parenti Giancarlo, Pijnappel W W M Pim, Roberts Mark, Scherer Thomas, Toscano Antonio, Vissing John, O'Sullivan Joe M, van Doorn Pieter A, Wenninger Stephan, van der Ploeg Ans T
Temporal evolution of primary angiitis of the central nervous system (PACNS) on MRI following immunosuppressant treatment.
Wagner F, Almeida G, Willems E, Weber J, Geiss J, Hundsberger T, Mordasini P, Wildermuth S, Leschka S, Wälti S, Dietrich T, Fischer T. Temporal evolution of primary angiitis of the central nervous system (PACNS) on MRI following immunosuppressant treatment. Insights Imaging 2024; 15:140.
09.06.2024Temporal evolution of primary angiitis of the central nervous system (PACNS) on MRI following immunosuppressant treatment.
09.06.2024Insights Imaging 2024; 15:140
Wagner Franca, Almeida Gonçalo G, Willems Erik, Weber Johannes, Geiss Johannes, Hundsberger Thomas, Mordasini Pasquale, Wildermuth Simon, Leschka Sebastian, Wälti Stephan, Dietrich Tobias Johannes, Fischer Tim Steffen
An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.
Jank P, Karn T, van Mackelenbergh M, Lindner J, Treue D, Huober J, Engels K, Solbach C, Diebold K, Marme F, Müller V, Schneeweiss A, Sinn H, Fehm T, Schem C, Stickeler E, Fasching P, Budczies J, Felder B, Nekljudova V, Holtschmidt J, Untch M, Denkert C, Loibl S. An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials. Clin Cancer Res 2024
05.06.2024An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.
05.06.2024Clin Cancer Res 2024
Jank Paul, Karn Thomas, van Mackelenbergh Marion T, Lindner Judith L, Treue Denise, Huober Jens, Engels Knut, Solbach Christine, Diebold Kurt, Marme Frederik, Müller Volkmar, Schneeweiss Andreas, Sinn Hans-Peter, Fehm Tanja N, Schem Christian, Stickeler Elmar, Fasching Peter Andreas, Budczies Jan, Felder Bärbel, Nekljudova Valentina, Holtschmidt Johannes, Untch Michael, Denkert Carsten, Loibl Sibylle
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.
Goetz M, Toi M, Huober J, Sohn J, Trédan O, Park I, Campone M, Chen S, Manso L, Paluch-Shimon S, Freedman O, O'Shaughnessy J, Pivot X, Tolaney S, Hurvitz S, Llombart-Cussac A, Andre V, Saha A, van Hal G, Shahir A, Iwata H, Johnston S. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3. Ann Oncol 2024
08.05.2024Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.
08.05.2024Ann Oncol 2024
Goetz Matthew P, Toi Masakazu, Huober Jens, Sohn Joo Hyuk, Trédan Olivier, Park In Hae, Campone Mario, Chen S-C, Manso L M, Paluch-Shimon Shani, Freedman Orit C, O'Shaughnessy Joyce, Pivot X, Tolaney Sara M, Hurvitz Sara A, Llombart-Cussac Antonio, Andre Valerie A M, Saha A, van Hal G, Shahir Ashwin, Iwata H, Johnston Stephen R D
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.
Goetz M, Cicin I, Testa L, Tolaney S, Huober J, Guarneri V, Johnston S, Martín M, Rastogi P, Harbeck N, Shahir A, Wei R, Andre V, Rugo H, O'Shaughnessy J. Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study. NPJ Breast Cancer 2024; 10:34.
26.04.2024Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.
26.04.2024NPJ Breast Cancer 2024; 10:34
Goetz Matthew P, Cicin Irfan, Testa Laura, Tolaney Sara M, Huober Jens, Guarneri Valentina, Johnston Stephen R D, Martín Miguel, Rastogi Priya, Harbeck Nadia, Shahir Ashwin, Wei Ran, Andre Valerie A M, Rugo Hope S, O'Shaughnessy Joyce
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
Meyer-Wilmes P, Huober J, Untch M, Blohmer J, Janni W, Denkert C, Klare P, Link T, Rhiem K, Bayer C, Reinisch M, Bjelic-Radisic V, Zahm D, Hanusch C, Solbach C, Heinrich G, Hartkopf A, Schneeweiss A, Fasching P, Filmann N, Nekljudova V, Holtschmidt J, Stickeler E, Loibl S. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). ESMO Open 2024; 9:103009.
24.04.2024Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
24.04.2024ESMO Open 2024; 9:103009
Meyer-Wilmes P, Huober Jens, Untch Michael, Blohmer J-U, Janni Wolfgang, Denkert Carsten, Klare Peter, Link Theresa, Rhiem Kerstin, Bayer C, Reinisch Mattea, Bjelic-Radisic Vesna, Zahm Dirk Michael, Hanusch Claus, Solbach Christine, Heinrich Georg, Hartkopf Andreas D, Schneeweiss Andreas, Fasching Peter Andreas, Filmann N, Nekljudova Valentina, Holtschmidt J, Stickeler Elmar, Loibl Sibylle
Electrodiagnostic Biomarkers in Paraneoplastic Retinopathy.
Gougoulakis L, Rothermundt C, Flynn M, Jörger M, Todorova M. Electrodiagnostic Biomarkers in Paraneoplastic Retinopathy. Klin Monbl Augenheilkd 2024; 241:510-524.
23.04.2024Electrodiagnostic Biomarkers in Paraneoplastic Retinopathy.
23.04.2024Klin Monbl Augenheilkd 2024; 241:510-524
Gougoulakis Laura Sophie, Rothermundt Christian, Flynn Marie-Claire, Jörger Markus, Todorova Margarita
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024.
Park-Simon T, Müller V, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Ditsch N, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf A, Heil J, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe H, Krug D, Kühn T, Kümmel S, Loibl S, Luftner D, Lux M, Maass N, Mundhenke C, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Wuerstlein R, Wöckel A, Janni W, Thill M. Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024. Breast Care (Basel) 2024; 19:165-182.
18.04.2024Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024.
18.04.2024Breast Care (Basel) 2024; 19:165-182
Park-Simon Tjoung-Won, Müller Volkmar, Albert Ute-Susann, Banys-Paluchowski Maggie, Bauerfeind Ingo, Blohmer Jens-Uwe, Budach Wilfried, Dall Peter, Ditsch Nina, Fallenberg Eva Maria, Fasching Peter Andreas, Fehm Tanja N, Friedrich Michael, Gerber Bernd, Gluz Oleg, Harbeck Nadia, Hartkopf Andreas Daniel, Heil Jörg, Huober Jens, Jackisch Christian, Kolberg-Liedtke Cornelia, Kreipe Hans-Heinrich, Krug David, Kühn Thorsten, Kümmel Sherko, Loibl Sibylle, Luftner Diana, Lux Michael Patrick, Maass Nicolai, Mundhenke Christoph, Reimer Toralf, Rhiem Kerstin, Rody Achim, Schmidt Marcus, Schneeweiss Andreas, Schütz Florian, Sinn Hans-Peter, Solbach Christine, Solomayer Erich-Franz, Stickeler Elmar, Thomssen Christoph, Untch Michael, Witzel Isabell, Wuerstlein Rachel, Wöckel Achim, Janni Wolfgang, Thill Marc
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024.
Thill M, Janni W, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Ditsch N, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf A, Heil J, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe H, Krug D, Kühn T, Kümmel S, Loibl S, Luftner D, Lux M, Maass N, Mundhenke C, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Wuerstlein R, Müller V, Park-Simon T. Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024. Breast Care (Basel) 2024; 19:183-191.
10.04.2024Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024.
10.04.2024Breast Care (Basel) 2024; 19:183-191
Thill Marc, Janni Wolfgang, Albert Ute-Susann, Banys-Paluchowski Maggie, Bauerfeind Ingo, Blohmer Jens-Uwe, Budach Wilfried, Dall Peter, Ditsch Nina, Fallenberg Eva Maria, Fasching Peter Andreas, Fehm Tanja N, Friedrich Michael, Gerber Bernd, Gluz Oleg, Harbeck Nadia, Hartkopf Andreas D, Heil Jörg, Huober Jens, Jackisch Christian, Kolberg-Liedtke Cornelia, Kreipe Hans-Heinrich, Krug David, Kühn Thorsten, Kümmel Sherko, Loibl Sibylle, Luftner Diana, Lux Michael Patrick, Maass Nicolai, Mundhenke Christoph, Reimer Toralf, Rhiem Kerstin, Rody Achim, Schmidt Marcus, Schneeweiss Andreas, Schütz Florian, Sinn Hans-Peter, Solbach Christine, Solomayer Erich-Franz, Stickeler Elmar, Thomssen Christoph, Untch Michael, Witzel Isabell, Wöckel Achim, Wuerstlein Rachel, Müller Volkmar, Park-Simon Tjoung-Won
Baseline CD4 and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients.
Massa C, Karn T, Weber K, Schneeweiss A, Hanusch C, Blohmer J, Zahm D, Jackisch C, van Mackelenbergh M, Thomalla J, Marme F, Huober J, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching P, Untch M, Loibl S, Denkert C, Seliger B. Baseline CD4 and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients. Clin Transl Med 2024; 14:e1617.
01.04.2024Baseline CD4 and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients.
01.04.2024Clin Transl Med 2024; 14:e1617
Massa Chiara, Karn Thomas, Weber Karsten E, Schneeweiss Andreas, Hanusch Claus, Blohmer Jens-Uwe, Zahm Dirk-Michael, Jackisch Christian, van Mackelenbergh Marion T, Thomalla Jörg, Marme Frederik, Huober Jens, Müller Volkmar, Schem Christian, Mueller Anja, Stickeler Elmar, Biehl Katharina, Fasching Peter Andreas, Untch Michael, Loibl Sibylle, Denkert Carsten, Seliger Barbara
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
Fernandez-Martinez A, Rediti M, Tang G, Pascual T, Hoadley K, Venet D, Rashid N, Spears P, Islam N, El-Abed S, Bliss J, Lambertini M, Di Cosimo S, Huober J, Goerlitz D, Hu R, Lucas P, Swain S, Sotiriou C, Perou C, Carey L. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials. JAMA Oncol 2024
28.03.2024Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
28.03.2024JAMA Oncol 2024
Fernandez-Martinez Aranzazu, Rediti Mattia, Tang Gong, Pascual Tomás, Hoadley Katherine A, Venet David, Rashid Naim U, Spears Patricia A, Islam N, El-Abed Sarra, Bliss Judith, Lambertini Matteo, Di Cosimo Serena, Huober Jens, Goerlitz David, Hu Rong, Lucas Peter C, Swain Sandra M, Sotiriou Christos, Perou Charles M, Carey Lisa A
Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference-a German expert perspective.
Krug D, Banys-Paluchowski M, Brucker S, Denkert C, Ditsch N, Fasching P, Haidinger R, Harbeck N, Heil J, Huober J, Jackisch C, Janni W, Kolberg H, Loibl S, Luftner D, van Mackelenbergh M, Radosa J, Reimer T, Welslau M, Wuerstlein R, Untch M, Budach W. Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference-a German expert perspective. Strahlenther Onkol 2024
23.02.2024Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference-a German expert perspective.
23.02.2024Strahlenther Onkol 2024
Krug David, Banys-Paluchowski Maggie, Brucker Sara Y, Denkert Carsten, Ditsch Nina, Fasching Peter Andreas, Haidinger Renate, Harbeck Nadia, Heil Jörg, Huober Jens, Jackisch Christian, Janni Wolfgang, Kolberg Hans-Christian, Loibl Sibylle, Luftner Diana, van Mackelenbergh Marion T, Radosa Julia C, Reimer Toralf, Welslau Manfred, Wuerstlein Rachel, Untch Michael, Budach Wilfried
Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?-Reply.
Huober J, Thürlimann B, Dietrich D. Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?-Reply. JAMA Oncol 2024
08.02.2024Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?-Reply.
08.02.2024JAMA Oncol 2024
Huober Jens, Thürlimann Beat, Dietrich Daniel